SARomics Biostructures’ state of the art platform is built on many years of extensive expertise and experience in the fields of protein crystallization, X-ray crystallography and protein NMR spectroscopy. We offer a broad range of services which cover all aspects of structural biology:
• Gene-to-structure, FastLaneTM Standard & FastLaneTM Premium structures
• Protein NMR spectroscopy
• Protein expression, purification & crystallization
• Biophysical methods for protein characterization
• A catalogue of high purity crystallization grade recombinant proteins
The SARomics Biostructures team has also gathered many years of experience in biophysical characterization, crystallization and structure determination of antibody:antigen complexes. By combining NMR spectroscopy and X-ray crystallography, we can provide detailed characterization of biosimilars high order structure (HOS), including an analysis of its comparability with the originator antibody.
Please follow the links below for details of the services.
SARomics Biostructures is fully operational in these corona-times!
SARomics Biostructures together with its partner, Red Glead Discovery, join LundaGUARD, a consortium aimed at responding to present and future threats from infectious agents. Read more…
Japanese and French presentation of SARomics Biostructures is now available!
SARomics Biostructures together with its partners, Red Glead Discovery and Sahlgrenska Translational Melanoma Group, receive Swedish Government Swelife financing towards an innovative, effective and tolerable epigenetic cancer therapy for an orphan cancer indication. Press release..
Visit our blog to view additional company news!
SARomics Biostructures’ integrated drug discovery services platform, which is run in close cooperation with Red Glead Discovery, combines key capabilities from a number of disciplines, which include:
• Weak Affinity Chromatography (WAC™)
• Nuclear Magnetic Resonance spectroscopy (NMR)
• Thermal Shift Assay (DSF)
• Computational chemistry
• Biochemical & cell-based screening
Our proprietary weak affinity chromatography-based hit identification method has a proven track record of providing high quality lead fragments in projects which had often failed earlier screening efforts. The platform offers a variety of both pre-determined and custom drug discovery service packages.